BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Phase 1

Terminated

Conditions: Rhabdomyosarcoma
Osteosarcoma
Ewing Sarcoma
Neuroblastoma
Relapsed or Refractory Solid Tumors or Lymphoma in Children

Interventions: Drug: Copanlisib (BAY806946)

First Posted Date: 2018-03-08

Last Posted Date: 2023-12-04

Lead Sponsor: Bayer

Target Recruit Count: 31

Registration Number: NCT03458728

Locations: 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
The Children's Hospital, Aurora, Colorado, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States

and more 11 locations

Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)

Completed

Conditions: Heart Failure

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)

First Posted Date: 2018-03-06

Last Posted Date: 2023-11-07

Lead Sponsor: Bayer

Target Recruit Count: 552

Registration Number: NCT03455439

Locations: 🇪🇸
Many Locations, Multiple Locations, Spain

A Study to Assess Menstrual Cramp Pain Associated With Primary Dysmenorrhea

Phase 4

Completed

Conditions: Dysmenorrhea

Interventions: Drug: Naproxen Sodium, (Aleve, BAY117031)
Drug: Acetaminophen (Tylenol Extra Strength)

First Posted Date: 2018-02-28

Last Posted Date: 2019-10-28

Lead Sponsor: Bayer

Target Recruit Count: 201

Registration Number: NCT03448536

Locations: 🇺🇸
Synexus US, LP- Plano, Plano, Texas, United States
🇺🇸
Radiant Research, Inc., Dallas, Texas, United States

A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure

Phase 4

Completed

Conditions: Rhinitis, Allergic

Interventions: Drug: loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D)
Drug: Placebo tablet
Drug: Fluticasone Propionate
Drug: Placebo spray

First Posted Date: 2018-02-23

Last Posted Date: 2019-12-20

Lead Sponsor: Bayer

Target Recruit Count: 82

Registration Number: NCT03443843

Locations: 🇨🇦
Kingston General Hospital, Kingston, Ontario, Canada

In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control

Not Applicable

Completed

Conditions: Atopic Dermatitis

Interventions: Device: Modified Diprobase formulation (BAY987534)

First Posted Date: 2018-02-22

Last Posted Date: 2020-07-24

Lead Sponsor: Bayer

Target Recruit Count: 40

Registration Number: NCT03441568

Locations: 🇬🇧
West Timperley Medical Centre, Altrincham, United Kingdom

BAY2328065 Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Relative Bioavailability, Food Effect

Phase 1

Completed

Conditions: Endometriosis

Interventions: Drug: Placebo
Drug: BAY2328065

First Posted Date: 2018-02-09

Last Posted Date: 2024-02-29

Lead Sponsor: Bayer

Target Recruit Count: 72

Registration Number: NCT03427788

Locations: 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany

A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fed Conditions

Phase 1

Completed

Conditions: Clinical Pharmacology

Interventions: Drug: Naproxen sodium and diphenhydramine hydrochloride soft capsules
Drug: Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve PM, BAY98-7111)

First Posted Date: 2018-02-06

Last Posted Date: 2019-03-20

Lead Sponsor: Bayer

Target Recruit Count: 60

Registration Number: NCT03424135

Locations: 🇺🇸
ICON Development Solutions, LLC, San Antonio, Texas, United States

Multi-academic Center Study of Xofigo Patients

Completed

Conditions: Prostate Cancer, Castration Resistant

Interventions: Drug: Xofigo
Drug: Taxotere
Drug: Jevtana

First Posted Date: 2018-02-05

Last Posted Date: 2020-10-22

Lead Sponsor: Bayer

Target Recruit Count: 150

Registration Number: NCT03419442

Locations: 🇺🇸
Bayer US, Whippany, New Jersey, United States

A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects

Phase 3

Completed

Conditions: Anemia
Renal Insufficiency, Chronic

Interventions: Drug: Molidustat (BAY85-3934)

First Posted Date: 2018-02-01

Last Posted Date: 2021-01-29

Lead Sponsor: Bayer

Target Recruit Count: 51

Registration Number: NCT03418168

Locations: 🇯🇵
Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan
🇯🇵
Fukushima Medical University Hospital, Fukushima, Japan
🇯🇵
Asahi University Hospital, Gifu, Japan

and more 24 locations

Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)

Completed

Conditions: Macular Degeneration

Interventions: Drug: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)

First Posted Date: 2018-01-26

Last Posted Date: 2019-12-05

Lead Sponsor: Bayer

Target Recruit Count: 116

Registration Number: NCT03411941

Locations: 🇪🇸
Many locations, Multiple Locations, Spain

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy